American Society of Hematology

Figure 1.

Binding of anti-α2 I-domain mAbs to α2 I-His and to resting platelets. (A) Binding of control mAb MOPC-21 (•) or selected anti-α2 I-domain mAbs Gi9 (○), 1D12 (▪), and IAC-1 (□) to α2 I-domain-coated wells; bound mAbs were detected with GAM-HRP. (B) Staining of human platelets (PRP, 5 × 105 platelets/μL) with the indicated FITC-labeled anti-α2 I-domain mAbs (20 μg/mL) and analysis by flow cytometry.

Binding of anti-α₂ I-domain mAbs to α₂ I-His and to resting platelets. (A) Binding of control mAb MOPC-21 (•) or selected anti-α₂ I-domain mAbs Gi9 (○), 1D12 (▪), and IAC-1 (□) to α₂ I-domain-coated wells; bound mAbs were detected with GAM-HRP. (B) Staining of human platelets (PRP, 5 × 10⁵ platelets/μL) with the indicated FITC-labeled anti-α₂ I-domain mAbs (20 μg/mL) and analysis by flow cytometry.

This Feature Is Available To Subscribers Only